Clinical Trials

Hodgkin Disease, Recurrence

NCT03160079 2025-11-10

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts

16 enrolled 14 charts

Burkitt Lymphoma, Recurrence

NCT03010176 2025-10-29

MK-1454-001

Phase 1 Completed

156 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma

NCT04875195 2025-10-29

MK-3475-B68

Phase 2 Completed

66 enrolled 16 charts

Hodgkin Disease

NCT05922904 2025-10-10

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

25 enrolled

Phase 1 Active not recruiting

Hodgkin Disease

NCT03150329 2025-09-03

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

52 enrolled 13 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05507541 2025-08-29

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

10 enrolled

Phase 1 Active not recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03240211 2025-08-26

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

37 enrolled

Lymphoma, T-Cell

NCT06812858 2025-08-19

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

Phase 2 Recruiting

83 enrolled

Hodgkin Disease

NCT03331341 2025-08-05

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

50 enrolled 10 charts

Hodgkin Disease

NCT03179930 2025-07-23

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

47 enrolled

Lymphoma, Recurrence

NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Phase 2 Terminated

18 enrolled 14 charts

GastrointestinalGenitourinaryLymphoidThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Phase 1 Completed

56 enrolled 19 charts

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT03598998 2025-06-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Phase 1/2 Active not recruiting

13 enrolled 12 charts

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

51 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03512405 2025-05-30

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

36 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

17 enrolled

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT03035331 2025-05-16

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

LymphoidOther hematologic neoplasm

11 enrolled 12 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03286114 2025-05-11

Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

Phase 1 Terminated

16 enrolled 13 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03179917 2025-05-07

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

22 enrolled

Hodgkin Disease

NCT03983668 2025-04-24

CMP-001 for Relapsed and Refractory Lymphoma

14 enrolled

Lymphoma

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Phase 2 Recruiting

71 enrolled

Phase EARLY_PHASE1 Active not recruiting

Hodgkin Disease

NCT04134325 2025-04-16

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

10 enrolled

Hodgkin Disease

NCT04317066 2025-04-06

KEYNOTE-A33

Phase 1 Completed

7 enrolled 13 charts

Phase 2 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma, B-Cell

NCT06045195 2025-04-06

Pembro-FLASH

40 enrolled

Hodgkin Disease

NCT04788043 2025-04-02

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

8 enrolled